Navigation Links
S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Date:12/1/2008

SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).

The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients. The Phase 1 part of the study will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518, and the Phase 2 component will assess the clinical benefits and continue to evaluate the safety profile of SB1518. The principal investigators are Dr. Andrew Roberts at the Royal Melbourne Hospital and Dr. John Seymour at the Peter MacCallum Cancer Centre.

"We are pleased with the advancement of our JAK2 inhibitor into a Phase 1/2 clinical trial in Australia as it exemplifies the expansion of our company's global development strategy," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518's strengths are in its exciting anti-proliferative and anti-tumor activity, as demonstrated by a range of in vitro and in vivo models, as well as its excellent tolerability. We believe this compound may eventually provide oncologists with a much needed and improved option to treat patients suffering from CIMF."

CIMF is a serious progressive and chronic condition whereby scar tissue develops in the bone marrow, resulting in a reduced ability to produce sufficient blood cells. Consequently, more blood cells are made in other organs, such as the liver and spleen which are not as efficient at blood cell production as the bone marrow. CIMF is characterized by an enlarged spleen and progressive anaemia. Current therapies for CIMF are mostly palliative in nature and survival rates can be short. While the actual cause of the disease is unknown, the JAK2 gene has been implicated i
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
2. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
5. Anpath Group, Inc. Advances Relationship With the Washington Metropolitan Area Transit Authority (Metro)
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
9. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
10. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
11. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015  Thoratec Corporation (NASDAQ: THOR ), a world ... restore failing hearts, announced today that Marta Antonucci ... International. This new Europe -based ... North America , including Europe ... Latin America , and reports directly to the Chief ...
(Date:5/1/2015)... 2015  Legendary actor and director Danny Glover ... campaign designed to educate and encourage patients with neurologic ... Affect (PBA) and to speak with their physician. The ... the ability to cry and laugh on cue and ... by people living with PBA episodes. While ...
(Date:5/1/2015)... CITY, Calif. , May 1, 2015  AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that Timothy E. Morris , chief financial ...  Details of the events are as follows: ... May 5 Location:  The Omni Berkshire Place, ...
Breaking Medicine Technology:Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2
... proud to announce its conference keynote speakers include: Centers ... CBS Evening News Anchor Katie Couric; U.S. ... U.S. Secretary of Commerce Gary Locke. Each will address ... leaders in Washington, D.C. October 18-20 during AdvaMed ...
... Arlington Medical Resources (AMR), a provider of premier ... finds that more than half of all European inpatients ... Sanofi-Aventis,s Clexane (marketed as Lovenox in the U.S. and ... The European Hospital Anticoagulant Market Guide is a ...
Cached Medicine Technology:AdvaMed 2010 Keynote Speakers Announced 2AdvaMed 2010 Keynote Speakers Announced 3European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane 2
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... 2015 It’s a pattern that won’t ... strikes anywhere on this planet, cyber scammers will immediately ... compassion for their own personal gain. And on ... Team) issued an alert titled “Nepal Earthquake Disaster ... citing the earthquake in Nepal. The scam emails may ...
(Date:5/2/2015)... Ohio (PRWEB) May 02, 2015 On ... Liverpool City Hospital (ELCH) gathered to celebrate improvements in ... River Valley Health Partners (RVHP), had zero acquired ventilator ... urinary catheter associated infections. ELCH was also recently named ... The management team at ELCH credited the teamwork of ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
(Date:5/1/2015)... Caicos Islands, BWI (PRWEB) May 02, 2015 ... website! It is http://www.thevenetiangracebay.com , and it ... it incorporates the stunning white and attractive turquoise hues ... study of Google, sixty seven percent of leisure travelers ... study showed that smartphones were used in the planning ...
Breaking Medicine News(10 mins):Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... fibrillation stop taking anti-clotting drugs, their stroke risk goes ... about the same whether they are taking warfarin or ... fibrillation is an abnormal heart rhythm in which the ...
... There is an association between the rs1051730-rs16969968 genotype and ... cancer risk is largely, if not entirely, mediated by ... April 25 in the Journal of the National ... to be associated with heaviness of smoking, lung cancer ...
... News) -- Heroin addicts often have an increased sensitivity ... the course of treatment with methadone or other opioids, ... California-Los Angeles sought to determine how increased sensitivity to ... addict moves from drug abuse to stabilization and eventually ...
... of care collaboration to diagnosis, treat and follow ... which require rapid, resource-intensive care and confer a ... April 24 in Circulation . Specifically, cardiovascular ... non-STEMI/unstable angina, out-of-hospital cardiac arrest (OHCA), acute aortic ...
... Mass. (April 25, 2012) Developmental biologists at Tufts ... organisms recognize and repair head and facial abnormalities. ... mechanism has been reported for the face and the ... has been rigorously analyzed through mathematical modeling. ...
... of ways to treat a heart attack CPR, aspirin, ... a new candidate: Intense light. "The study ... the risk of having a heart attack or suffering damage ... of anesthesiology, cardiology, and cell and developmental biology at ...
Cached Medicine News:Health News:Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat 2Health News:Genetic variants, tobacco exposure and lung cancer risk 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2Health News:Facial defects shown to self-repair 2Health News:Facial defects shown to self-repair 3Health News:Intense light prevents, treats heart attacks 2
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: